Muscular Dystrophy, Duchenne
"Muscular Dystrophy, Duchenne" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An X-linked recessive muscle disease caused by an inability to synthesize DYSTROPHIN, which is involved with maintaining the integrity of the sarcolemma. Muscle fibers undergo a process that features degeneration and regeneration. Clinical manifestations include proximal weakness in the first few years of life, pseudohypertrophy, cardiomyopathy (see MYOCARDIAL DISEASES), and an increased incidence of impaired mentation. Becker muscular dystrophy is a closely related condition featuring a later onset of disease (usually adolescence) and a slowly progressive course. (Adams et al., Principles of Neurology, 6th ed, p1415)
MeSH Number(s)
C05.651.534.500.300
C10.668.491.175.500.300
C16.320.322.562
C16.320.577.300
Concept/Terms
Muscular Dystrophy, Duchenne- Muscular Dystrophy, Duchenne
- Childhood Pseudohypertrophic Muscular Dystrophy
- Duchenne Muscular Dystrophy
- Dystrophy, Duchenne Muscular
- Duchenne-Type Progressive Muscular Dystrophy
- Duchenne Type Progressive Muscular Dystrophy
- Muscular Dystrophy, Pseudohypertrophic Progressive, Duchenne Type
- Muscular Dystrophy, Pseudohypertrophic
- Dystrophies, Pseudohypertrophic Muscular
- Dystrophy, Pseudohypertrophic Muscular
- Muscular Dystrophies, Pseudohypertrophic
- Pseudohypertrophic Muscular Dystrophies
- Pseudohypertrophic Muscular Dystrophy
- Muscular Dystrophy, Pseudohypertrophic, Childhood
- Progressive Muscular Dystrophy, Duchenne Type
- Pseudohypertrophic Childhood Muscular Dystrophy
- Pseudohypertrophic Muscular Dystrophy, Childhood
- Childhood Muscular Dystrophy, Pseudohypertrophic
- Muscular Dystrophy, Childhood, Pseudohypertrophic
Below are MeSH descriptors whose meaning is more general than "Muscular Dystrophy, Duchenne".
- Diseases [C]
- Musculoskeletal Diseases [C05]
- Muscular Diseases [C05.651]
- Muscular Disorders, Atrophic [C05.651.534]
- Muscular Dystrophies [C05.651.534.500]
- Muscular Dystrophy, Duchenne [C05.651.534.500.300]
- Nervous System Diseases [C10]
- Neuromuscular Diseases [C10.668]
- Muscular Diseases [C10.668.491]
- Muscular Disorders, Atrophic [C10.668.491.175]
- Muscular Dystrophies [C10.668.491.175.500]
- Muscular Dystrophy, Duchenne [C10.668.491.175.500.300]
- Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
- Genetic Diseases, Inborn [C16.320]
- Genetic Diseases, X-Linked [C16.320.322]
- Muscular Dystrophy, Duchenne [C16.320.322.562]
- Muscular Dystrophies [C16.320.577]
- Muscular Dystrophy, Duchenne [C16.320.577.300]
Below are MeSH descriptors whose meaning is more specific than "Muscular Dystrophy, Duchenne".
This graph shows the total number of publications written about "Muscular Dystrophy, Duchenne" by people in Harvard Catalyst Profiles by year, and whether "Muscular Dystrophy, Duchenne" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 1 | 1 | 2 |
| 2001 | 2 | 0 | 2 |
| 2002 | 4 | 2 | 6 |
| 2003 | 2 | 0 | 2 |
| 2004 | 0 | 3 | 3 |
| 2005 | 5 | 0 | 5 |
| 2006 | 4 | 0 | 4 |
| 2007 | 6 | 0 | 6 |
| 2008 | 4 | 1 | 5 |
| 2009 | 3 | 1 | 4 |
| 2010 | 7 | 0 | 7 |
| 2011 | 8 | 2 | 10 |
| 2012 | 1 | 1 | 2 |
| 2013 | 10 | 2 | 12 |
| 2014 | 10 | 3 | 13 |
| 2015 | 10 | 1 | 11 |
| 2016 | 11 | 1 | 12 |
| 2017 | 11 | 2 | 13 |
| 2018 | 12 | 1 | 13 |
| 2019 | 13 | 3 | 16 |
| 2020 | 8 | 1 | 9 |
| 2021 | 0 | 1 | 1 |
Below are the most recent publications written about "Muscular Dystrophy, Duchenne" by people in Profiles.
-
PrimeDesign software for rapid and simplified design of prime editing guide RNAs. Nat Commun. 2021 02 15; 12(1):1034.
-
Medical management of muscle weakness in Duchenne muscular dystrophy. PLoS One. 2020; 15(10):e0240687.
-
Enhanced dimethylarginine degradation improves coronary flow reserve and exercise tolerance in Duchenne muscular dystrophy carrier mice. Am J Physiol Heart Circ Physiol. 2020 09 01; 319(3):H582-H603.
-
Update on Muscular Dystrophies with Focus on Novel Treatments and Biomarkers. Curr Neurol Neurosci Rep. 2020 05 14; 20(6):14.
-
A role for connexin-43 in Duchenne muscular dystrophy cardiomyopathy. J Clin Invest. 2020 04 01; 130(4):1608-1610.
-
The Effectiveness and Value of Deflazacort and Exon-Skipping Therapies for the Management of Duchenne Muscular Dystrophy. J Manag Care Spec Pharm. 2020 Apr; 26(4):361-366.
-
Recombinant human insulin-like growth factor-1 therapy for 6?months improves growth but not motor function in boys with Duchenne muscular dystrophy. Muscle Nerve. 2020 05; 61(5):623-631.
-
Conference report on contractures in musculoskeletal and neurological conditions. Muscle Nerve. 2020 06; 61(6):740-744.
-
Assessment of Treatment Effect With Multiple Outcomes in 2 Clinical Trials of Patients With Duchenne Muscular Dystrophy. JAMA Netw Open. 2020 02 05; 3(2):e1921306.
-
The Value of Imaging and Composition-Based Biomarkers in Duchenne Muscular Dystrophy Clinical Trials. Neurotherapeutics. 2020 01; 17(1):142-152.